HomeBUSINESS
BUSINESS

Harvoni Top-Selling Drug in Japan in FY2016, Opdivo Jumps but Drop Expected for FY2017: Jiho Tally
(Aug.17.2017)

Gilead Sciences’ hepatitis C therapy Harvoni (ledipasvir + sofosbuvir) was the best-selling drug in Japan for the second straight year in FY2016 despite its year-on-year sales slide of nearly 40%, with Ono Pharmaceutical’s Opdivo (nivolumab) ranking second with a 4.9-fold leap, according to a Jiho tally ...
(LOG IN FOR FULL STORY)

News Calendar